- Previous Close
3.8500 - Open
3.8900 - Bid 3.9000 x --
- Ask 3.9100 x --
- Day's Range
3.8500 - 3.9300 - 52 Week Range
3.3200 - 4.8400 - Volume
14,032,294 - Avg. Volume
6,836,808 - Market Cap (intraday)
4.258B - Beta (5Y Monthly) --
- PE Ratio (TTM)
32.50 - EPS (TTM)
0.1200 - Earnings Date --
- Forward Dividend & Yield 0.09 (2.01%)
- Ex-Dividend Date Jun 14, 2024
- 1y Target Est
--
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. Its primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, and betamethasone product series. The company provides amino acid raw materials, as well as dosage forms, including injections, ointments, creams, hard capsules, pills, freeze-dried powder injections, inhalation preparations, and tablets. It exports its products to the United States, Southeast Asia, Europe, South America, Africa, and internationally. The company was founded in 1939 and is based in Tianjin, China. Tianjin Tianyao Pharmaceuticals Co., Ltd. operates as a subsidiary of Tianjin Pharmaceutical Group Co., Ltd.
www.tjpcty.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 600488.SS
View MorePerformance Overview: 600488.SS
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600488.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600488.SS
View MoreValuation Measures
Market Cap
4.20B
Enterprise Value
4.10B
Trailing P/E
31.56
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.31
Price/Book (mrq)
1.37
Enterprise Value/Revenue
1.27
Enterprise Value/EBITDA
7.42
Financial Highlights
Profitability and Income Statement
Profit Margin
4.15%
Return on Assets (ttm)
3.33%
Return on Equity (ttm)
5.45%
Revenue (ttm)
3.22B
Net Income Avi to Common (ttm)
133.45M
Diluted EPS (ttm)
0.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
638.46M
Total Debt/Equity (mrq)
13.74%
Levered Free Cash Flow (ttm)
479.61M